Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Positive infection test by microscopy for at least one of the following STH: T. trichiura, hookworms and/or larvae of S. stercoralis.~* Weight ≥15 Kg.~* Male or female, aged 5 to 18 years.~* Female participants who are ≥12 years old (or female post menarche) must have a negative urine pregnancy test at screening or at the time of randomization.~* Ability to take oral medication and willingness to comply with all study procedures.~* Parental acceptance to participate in the study by obtaining a signed and dated informed consent form approved by the Regulatory authorities. In addition, verbal assent will be obtained from children aged 12-18 years.~Exclusion Criteria:~* Intake of ALB, mebendazole and/or IVM, or any potentially interacting drug three months before screening.~* Residence outside the study area or planning to move away in the four weeks following recruitment.~* Epidemiological risk of infection by Loa loa.~* Serious medical illness, per investigator's criteria.~* Any participant's condition that would prevent the appropriate evaluation and followup, as per investigator's criteria.~* Known hypersensitivity to any components of either of the study treatment.~* Positive pregnancy urine test, pregnant or first week postpartum.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Albendazole (Type: ACTIVE_COMPARATOR): Albendazole 400 mg single dose
- FDCx1. Albendazole and Ivermectin Fixed Dose Coformulation (Type: EXPERIMENTAL): Single dose of a tablet of FDC 400mg18mg or 400mg9mg. (i) For participants \<45 kg of body weight at baseline: FDC of 400mg ALB 9mg IVM. (ii) For participants ≥45 kg of body weight at baseline: FDC of 400mg ALB18mg IVM
- FDCx3. Albendazole and Ivermectin Fixed Dose Coformulation 3 days (Type: EXPERIMENTAL): Daily dose of a tablet of FDC 400mg18mg or 400mg 9mg for 3 days. (i)For participants \<45 kg of body weight at baseline: FDC of 400mg ALB9mg IVM. (ii) For participants ≥45 kg of body weight at baseline: FDC of 400mg ALB 18mg IVM.

Based on this trial design, predict the completion outcome and termination type (if applicable).